Inhibitory effects of a luteinizing hormone‐releasing hormone agonist on basal and epidermal growth factor‐induced cell proliferation and metastasis‐associated properties in human epidermoid carcinoma a431 cells
Open Access
- 30 April 2002
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 99 (4) , 505-513
- https://doi.org/10.1002/ijc.10373
Abstract
The purpose of this study was to investigate the effects of a potent LHRH agonist, [D-Trp6]LHRH on the basal and EGF-induced cell proliferation and the metastasis-associated properties in A431 human epidermoid carcinoma. [D-Trp6]LHRH time-dependently inhibited the basal and EGF-stimulated growth of A431 cancer cells. It is assumed that phosphorylation/dephosphorylation of cellular proteins is highly related to cell growth. This study demonstrates that [D-Trp6]LHRH decreased the basal and EGF-induced total cellular kinase activity, particularly the tyrosine phosphorylation of several cellular proteins including the EGFR. In contrast, [D-Trp6]LHRH did not cause detectable changes in basal and EGF-stimulated serine/threonine phosphorylation of A431 cellular proteins. The inhibitory effect of [D-Trp6]LHRH on A431 cell proliferation was associated with apoptosis as evidenced by the cell morphology and DNA integrity (ladder pattern), the expression of interleukin 1β-converting enzyme (ICE) and activation of caspase. Furthermore, EGF could rescue the remaining attached A431 cells following [D-Trp6]LHRH treatment for 48 hr, which suggests that limited exposure to [D-Trp6]LHRH did not channel all cells to irreversible apoptotic process. We also determined the effects of [D-Trp6]LHRH on metastasis-associated properties in A431 cells. [D-Trp6]LHRH reduced both basal and EGF-stimulated secretion of MMP-9 and MMP-2. In addition, [D-Trp6]LHRH suppressed the basal and EGF-induced invasive activity of A431 cells based on an in vitro invasion assay. In conclusion, this study indicates that [D-Trp6]LHRH may act partly through activating tyrosine phosphatase activity to inhibit cell proliferation and the metastasis-associated properties of A431 cancer cells. Our work suggests that [D-Trp6]LHRH may be therapeutically useful in limiting the tumor growth and metastasis of some neoplasms.Keywords
This publication has 52 references indexed in Scilit:
- Luteinizing Hormone-Releasing Hormone Induces Nuclear Factor B-Activation and Inhibits Apoptosis in Ovarian Cancer CellsJournal of Clinical Endocrinology & Metabolism, 2000
- Luteinizing Hormone–Releasing Hormone Agonist Triptorelin and Antagonist Cetrorelix Inhibit EGF-Induced c-fos Expression in Human Gynecological CancersGynecologic Oncology, 2000
- Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145Journal of Clinical Endocrinology & Metabolism, 1996
- Evidence for coupling of phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membraneCancer, 1996
- Signalling pathways as target for anticancer drug developmentPharmacology & Therapeutics, 1994
- Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaPJournal of Clinical Endocrinology & Metabolism, 1992
- A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytesNature, 1992
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences, 1979
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970